I-MAB (FRA:0VY) Other Operating Expense : €-1.79 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Other Operating Expense?

I-MAB's Other Operating Expense for the six months ended in Dec. 2023 was €-1.79 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.79 Mil.

I-MAB's quarterly Other Operating Expense increased from Dec. 2022 (€-3.83 Mil) to Jun. 2023 (€-0.00 Mil) but then declined from Jun. 2023 (€-0.00 Mil) to Dec. 2023 (€-1.79 Mil).

I-MAB's annual Other Operating Expense declined from Dec. 2021 (€-1.61 Mil) to Dec. 2022 (€-3.83 Mil) but then increased from Dec. 2022 (€-3.83 Mil) to Dec. 2023 (€-1.79 Mil).

I-MAB Other Operating Expense Historical Data

The historical data trend for I-MAB's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Other Operating Expense Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

-0.07

-1.76

-1.61

-3.83

-1.79

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Operating Expense	Get a 7-Day Free Trial								-0.92	-	-3.83	-	-1.79

I-MAB Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.79 Mil.

I-MAB Other Operating Expense Related Terms

Thank you for viewing the detailed overview of I-MAB's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (FRA:0VY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (FRA:0VY) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

IMAB:USA

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.

I-MAB (FRA:0VY) Headlines

No Headlines